EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study

Rosa Natalia García-Pérez, Víctor Siles-Guerrero, Aida Elhadri-Egea, Gonzalo Piedrola-Maroto, Juan Manuel Guardia-Baena, María Hayón-Ponce, Martín López-de-la-Torre-Casares, Araceli Muñoz-Garach, Jose M. Romero-Márquez

Endocrines · 27.07.2026 · 7 (3) · 39

DOI: 10.3390/endocrines7030039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrines, online erschienen am 27.07.2026. Verfasst von Rosa Natalia García-Pérez und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes mellitus is commonly associated with obesity, metabolic liver disease, and chronic low-grade inflammation. Semaglutide is known to improve glycaemic control and body weight, but its real-world associations with hepatic markers, fibrosis-related indices, and systemic inflammatory parameters remain incompletely characterized. This study evaluated changes in metabolic, hepatic, and inflammatory parameters during injectable semaglutide treatment and explored whether these changes differed according to baseline disease status.

Methods

A retrospective observational study was conducted in patients with type 2 diabetes treated with injectable semaglutide 1 mg/week and followed for six months. Anthropometric, metabolic, hepatic, and inflammatory variables were collected at baseline and follow-up, including liver enzymes, the Fibrosis-4 (FIB-4) index, and the systemic immune–inflammation (SII) index. Analyses included correlation analyses and exploratory stratification according to baseline fibrosis risk and inflammatory status.

Results

Semaglutide treatment was associated with significant reductions in body weight, body mass index, fasting glucose, HbA1c, and triglyceride levels. Alanine and aspartate aminotransferase levels decreased significantly, consistent with a reduction in liver enzyme abnormalities during follow-up. No significant overall changes were observed in FIB-4, an indirect fibrosis-related index, or in SII, an indirect hematological inflammatory index. However, exploratory stratified analyses suggested that patients with higher baseline FIB-4-estimated fibrosis risk or elevated SII values showed greater reductions in these indices, whereas those with low baseline risk showed no relevant changes.

Conclusions

In routine clinical practice, six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus. Findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices and the baseline-dependent patterns observed were exploratory and hypothesis-generating.

Zitieren

APA

García-Pérez, R. N., Siles-Guerrero, V., Elhadri-Egea, A., Piedrola-Maroto, G., Guardia-Baena, J. M., Hayón-Ponce, M., López-de-la-Torre-Casares, M., Muñoz-Garach, A., & Romero-Márquez, J. M. (2026). Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study. Endocrines, 7(3), 39. https://doi.org/10.3390/endocrines7030039

Vancouver

García-Pérez RN, Siles-Guerrero V, Elhadri-Egea A, Piedrola-Maroto G, Guardia-Baena JM, Hayón-Ponce M, et al. Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study. Endocrines. 2026;7(3):39. doi:10.3390/endocrines7030039

BibTeX
@article{GarcaPrez2026,
  author = {García-Pérez, Rosa Natalia and Siles-Guerrero, Víctor and Elhadri-Egea, Aida and Piedrola-Maroto, Gonzalo and Guardia-Baena, Juan Manuel and Hayón-Ponce, María and López-de-la-Torre-Casares, Martín and Muñoz-Garach, Araceli and Romero-Márquez, Jose M.},
  title = {Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study},
  journal = {Endocrines},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {39},
  doi = {10.3390/endocrines7030039}
}
Kostenlos starten →